Test study for ELOVL4-related Stargardt-like vision loss
Part of Eyes & vision clinical trials.
This trial is for people with a specific genetic cause of Stargardt-like macular dystrophy due to ELOVL4 mutations. It uses regular eye tests and imaging to see how the condition is affected and whether the study approach might help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) agree to follow all study visits and procedures for the full study period
- You are at least 10 years old
- You can do the required vision tests and eye scan pictures (imaging)
- Genetic testing shows an ELOVL4 mutation that matches Stargardt-like macular dystrophy
- You (or your guardian) understand the study and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how Stargardt disease and similar eye conditions change over time in children and adults. It aims to learn more about the disease progression to help develop future treatments.
This study tests a single injection of ASP2020 in the eye to see if it is safe and if it can help improve vision for people with Stargardt disease or similar inherited eye conditions.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
This trial tests a new gene therapy called ZVS106e for people with inherited retinal degeneration caused by changes in both copies of the ABCA4 gene. The therapy aims to slow or stop vision loss, and the study will check if it is safe and if it works.
Hear when a new Stargardt-Like Macular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.